Analysts Turn Mixed On Cyclacel Pharmaceuticals, Inc. (CYCC), Microsoft Corporation (MSFT) - Financial Mercury

The shares of Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) has been pegged with a rating of Buy by Ladenburg Thalmann in its latest research note that was published on September 7th, 2018. Ladenburg Thalmann wasn’t the only research firm that published a report of Cyclacel Pharmaceuticals, Inc., with other equities research analysts also giving their opinion on the stock. H.C. Wainwright advised investors in its research note published on October 16th, 2015, to Buy the CYCC stock while also putting a $5 price target. The stock had earned Buy rating from Roth Capital when it published its report on February 4th, 2010. That day the Roth Capital set price target on the stock to $7. The stock was given Buy rating by Merriman in its report released on October 28th, 2009. Piper Jaffray was of a view that CYCC is Buy in its latest report on August 12th, 2008 while giving it a price target of $5. Needham & Co thinks that CYCC is worth Buy rating. This was contained in the firm’s report on March 12th, 2008 in which the stock’s price target was also moved to $7.

Amongst the analysts that rated the stock, 0 have recommended investors to sell it, 0 believe it has the potential for further growth, thus rating it as Hold while 1 advised investors to purchase the stock. The consensus currently stands at a Hold while its average price target is $7.00. The price of the stock the last time has raised by 49.61% from its Week high price while it is raised higher than its 52-Week low price. A look at the stock’s other technical shows that its 14-day RSI now stands at 57.33.

The shares of the company added by 22.26% during the trading session on Friday, reaching a low of $0.705 while ending the day at $0.76. During the trading session, a total of 27.89 million shares were traded which represents a -3709550.46% decline from the average session volume which is 751.84K shares. CYCC had ended its last session trading at 0.62. Cyclacel Pharmaceuticals, Inc. currently has a market cap of $10.70M while its P/E earnings growth sits at 53.49, with a beta of 3.34. Cyclacel Pharmaceuticals, Inc. debt-to-equity ratio currently stands at 0.00, while its quick ratio hovers at 8.10. CYCC 52-week low price stands at $0.51 while its 52-week high price is $1.87.

The company in its last quarterly report recorded -$0.14 earnings per share which is above the -$0.20 predicted by most analysts. In the second quarter last year, the firm recorded -$0.17 earnings per share. Compared to the same quarter last year, the firm’s revenue was down by -21.43%. Cyclacel Pharmaceuticals, Inc. has the potential to record -0.64 EPS for the current fiscal year, according to equities analysts.

Investment analysts at BofA/Merrill published a research note on April 25th, 2019 where it informed investors and clients that Microsoft Corporation (NASDAQ:MSFT) is now rated as Buy. Their price target on the stock stands at $155. H.C. Wainwright also rated MSFT as Initiated on October 16th, 2015, with its price target of $10 suggesting that MSFT could surge by 11.82% from its current share price. Even though the stock has been trading at $126.18/share, analysts expect it to surge higher by 0.05% to reach $143.16/share. It started the day trading at $127.42 and traded between $125.97 and $126.24 throughout the trading session.

A look at its technical shows that MSFT’s 50-day SMA is 123.02 while its 200-day SMA stands at 111.77. The stock has a high of $131.37 for the year while the low is $93.96. The company’s P/E ratio currently sits at 28.15, while the P/B ratio is 10.21. At the moment, only of Microsoft Corporation shares were sold short. The company’s average trading volume currently stands at 24.79M shares, which means that the short-interest ratio is just 1.81 days. Over the past seven days, the company moved, with its shift of -1.43%. Looking further, the stock has raised 13.13% over the past 90 days while it gained 24.12% over the last six months.

The change in the stock’s fortunes has led to several institutional investors altering their holdings of the stock. The Vanguard Group Inc bought more MSFT shares, increasing its portfolio by +0.36% during the last quarter. This move now sees The Vanguard Group Inc purchasing 2,157,681 shares in the last quarter, thus it now holds 594,486,899 shares of MSFT, with a total valuation of $77,639,989,009. BlackRock Fund Advisors meanwhile sold more MSFT shares in the recently filed quarter, changing its stake to $43,922,443,191 worth of shares. SSgA Funds Management Inc followed the path by increasing its MSFT portfolio by +3.13% in the quarter. This means that SSgA Funds Management Inc bought 9,503,045 shares in the last quarter and now controls 313,113,425 shares of the MSFT stock, with the valuation hitting $40,892,613,305.

Similarly, T Rowe Price Associates Inc increased its Microsoft Corporation shares by +0.66% during the recently filed quarter. After buying 1,268,111 shares in the last quarter, the firm now controls 193,860,926 shares of Microsoft Corporation which are valued at $25,318,236,936. In the same vein, Capital Research Management Co increased its Microsoft Corporation shares by during the most recent reported quarter. The firm bought 3,692,793 shares during the quarter which increased its stakes to 189,066,145 shares and is now valued at $24,692,038,537. Following these latest developments, around 0.10% of Microsoft Corporation stocks are owned by institutional investors and hedge funds.

Let's block ads! (Why?)